Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR-2 peptide
- Development stage
- Preclinical
- Lead developer
- Virginia Commonwealth University
- Modality
- Peptides
- Administration
- Parenteral
01
Overview
CR-2 peptide is an experimental therapeutic peptide derived from the CR-2 domain of the GATAD2A protein. It is designed to disrupt the protein-protein interaction between GATAD2A and CHD4, which are critical components of the MBD2-NuRD (Nucleosome Remodeling and Deacetylase) complex. This complex plays a central role in the epigenetic silencing of fetal hemoglobin (HbF) in adult erythroid cells. By binding to the interface between the C-terminal domains 1 and 2 (CTD1/2) of CHD4, the CR-2 peptide prevents the recruitment of CHD4 to the core NuRD complex, thereby relieving the transcriptional silencing of the HBG promoter. This mechanism leads to the induction of high levels of HbF, offering a potential therapeutic strategy for patients with sickle cell disease and beta-thalassemia. The peptide was characterized through structural studies using AlphaFold3 and validated in cellular models by researchers at Virginia Commonwealth University and the University of North Carolina.
- Other names
- GATAD2A CR-2 peptideGATAD-2A CR-2 peptideGATAD 2A CR-2 peptide
02
Targets
CHD4 (Chromodomain-helicase-DNA-binding protein 4)GATAD2A (GATA zinc finger domain-containing protein 2A)
Beyond the preview
Go deeper on CR-2 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CR-2 peptide.